Effect of thyroid function on anxiety, depression, fatigue and sleep disorder in patients with AMI

Status

Active, not recruiting

Phases

Early Phase 1

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR2100048821

Enrollment

Unknown

Registered

2021-07-18

Start date

2021-07-18

Completion date

Unknown

Last updated

2022-03-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

coronary artery disease

Interventions

case group:Nil

Eligibility

Sex/Gender

All

Age

18 Years to 75 Years

Inclusion criteria

Inclusion criteria: 1. The diagnosis of AMI is clear; 2. Survivors aged from 18 to 75 years; 3. New acute myocardial infarction; 4. Informed consent and voluntary participation in this study.

Exclusion criteria

Exclusion criteria: 1. Disturbance of consciousness, low cognitive ability, aphasia, severe comprehension disorder, cancer or other neuropsychiatric disorders and refusal to participate in the research; 2. Previous thyroid diseases except benign nodules; 3. Fatigue, anxiety, depression, weakness and sleep disorder 1 month before AMI; 4. Taking any drug (including antidepressant, estrogen, androgen, amiodarone, lithium and glucocorticoid) that may cause changes in mental state or thyroid function; 5. Patients with severe heart, liver, kidney, lung dysfunction and malignant tumor; 6. Patients with incomplete thyroid function examination and significant lack of clinical data during hospitalization.

Design outcomes

Primary

Measure	Time frame
thyroid function;	—

Countries

China

Contacts

Public ContactLiu Naifeng

School of Medicine, Southeast University

liunf@seu.edu.cn+86 13805187701

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026